Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
11(34%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
9
28%
Ph phase_4
14
44%
Ph not_applicable
4
13%
Ph phase_2
2
6%

Phase Distribution

0

Early Stage

2

Mid Stage

23

Late Stage

Phase Distribution29 total trials
Phase 2Efficacy & side effects
2(6.9%)
Phase 3Large-scale testing
9(31.0%)
Phase 4Post-market surveillance
14(48.3%)
N/ANon-phased studies
4(13.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

11

trials recruiting

Total Trials

32

all time

Status Distribution
Active(25)
Completed(6)
Other(1)

Detailed Status

Not yet recruiting13
Recruiting10
Completed6
Active, not recruiting1
unknown1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
11
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (6.9%)
Phase 39 (31.0%)
Phase 414 (48.3%)
N/A4 (13.8%)

Trials by Status

recruiting1031%
active_not_recruiting13%
unknown13%
enrolling_by_invitation13%
not_yet_recruiting1341%
completed619%

Recent Activity

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT06024746Phase 3

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Recruiting
NCT07717697

Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis

Not Yet Recruiting
NCT06033950Phase 3

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Recruiting
NCT07688928Not Applicable

Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism

Recruiting
NCT06008197Phase 3

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Recruiting
NCT06835322Phase 2

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Completed
NCT07594145Phase 2

Precision T1D Platform - New Therapies for Cardio-Renal Complications

Not Yet Recruiting
NCT07585526Not Applicable

Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.

Not Yet Recruiting
NCT07523867Phase 4

Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study

Not Yet Recruiting
NCT07575672Phase 3

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

Not Yet Recruiting
NCT07547878Phase 4

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Not Yet Recruiting
NCT07537088Phase 4

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

Not Yet Recruiting
NCT06058585Phase 3

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting
NCT07442448Phase 4

Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure

Enrolling By Invitation
NCT06094920Phase 4

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Completed
NCT07351864Phase 4

Finerenone Plus SGLT2 Inhibitors in Heart Failure

Not Yet Recruiting
NCT07326631Not Applicable

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Not Yet Recruiting
NCT07270367Phase 3

Finerenone and Cardiac Remodeling

Not Yet Recruiting
NCT07239570Phase 4

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

Recruiting
NCT07235891Phase 4

Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
32